Moving forward, there is a need to develop more accurate CAR-T evaluation models to assess the anti-tumor efficacy of CD28-modified CAR-T cells, including metrics such as tumor-killing ability, differentiation, persistence, and exhaustion. Here, CD28 is linked to neoplasm.